granted
on 29 Nov 2023
Last Applicant/ Owned by
One Kendall Square, Building 600-700
Cambridge
MA
02139
Serial Number
90171690 filed on 10th Sep 2020
Registration Number
N/A
Correspondent Address
Tiffany D. Gehrke
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Research and development of pharmaceutical products; research and development in the field of bioscience; research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; research and development of pharmaceuRead More
Research and development of pharmaceutical products; research and development in the field of bioscience; research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; research and development of pharmaceutical preparations for the treatment of liver-based disorders, eye disorders and CNS disorders; research and development of oligonucleotide compounds for targeted RNA editing; research and development of oligonucleotide drug platforms for use in the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders
Custom manufacture of oligonucleotides or RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders
Oligonucleotide compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for use in RNA editing; Oligonucleotide compounds being a component in pharmaceutical preparations for use in base editing; Oligonucleotide compounds being a component in pharmaceutical preparations for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds that facilitate the editing of RNA base; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases
No 90171690
No Service Mark
No 33791/60005
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 30th Nov 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 29th Nov 2023 | SOU TEAS EXTENSION RECEIVED |
| 29th Nov 2023 | SOU EXTENSION 5 FILED |
| 29th Nov 2023 | SOU EXTENSION 5 GRANTED |
| 02th Jun 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 31st May 2023 | SOU TEAS EXTENSION RECEIVED |
| 31st May 2023 | SOU EXTENSION 4 FILED |
| 31st May 2023 | SOU EXTENSION 4 GRANTED |
| 25th May 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 25th May 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
